Fredun Pharmaceuticals Ltd (FREDUN) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Fredun Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Unaudited Standalone ....
Intimation · 05 Nov 2026, 5:30 am
Fredun Pharmaceuticals Schedules Board Meeting for Q2 FY27 Financial Results Fredun Pharmaceuticals Limited announced that its Board of Directors will meet on 5th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. In accordance with SEBI Insider Trading regulations, the company's trading window for dealing in its securities has been closed since 1st Oct'26 and will remain closed until 48 hours after the declaration of the financial results.
Allotment of 44000 Equity shares to Non- Promoters Allottees pursuant to conversion of Warrents.
Others (Uncategorized) · 24 Oct 2026, 12:00 am
Fredun Pharmaceuticals Allots 44,000 Equity Shares on Warrant Conversion Fredun Pharmaceuticals approved the allotment of 44,000 fully paid-up equity shares of face value Rs. 10 each on 23rd Oct'26 upon the conversion of 14,667 preferential warrants to three non-promoter allottees. Originally allotted on 29th Dec'25 at an issue price of Rs. 1,250 per warrant (with 25% paid upfront), warrant entitlements were adjusted following a 1:2 bonus issue to three equity shares per warrant. The allotment was executed after receiving the remaining balance consideration, leaving zero warrants outstanding for conversion among the applicants.
Allotment of 44,000 Equity Shares to Non-Promoter Allottees pursuant to conversion of 14,667 Warrants into Equity Shares, consequent to the 1:2 Bonus Issue.
Others (Uncategorized) · 23 Oct 2026, 11:56 pm
Fredun Pharmaceuticals Allots 44,000 Equity Shares on Warrant Conversion Fredun Pharmaceuticals approved the allotment of 44,000 fully paid-up equity shares of face value Rs. 10 each on 23rd Oct'26 following the conversion of 14,667 preferential warrants by three non-promoter allottees. Originally allotted on 29th Dec'25 at Rs. 1,250 per warrant with 25% upfront payment, the warrant entitlement was adjusted post a 1:2 bonus issue to three equity shares per warrant upon payment of the remaining consideration. Post conversion, zero warrants remain outstanding for these holders, and the newly allotted dematerialized shares rank pari passu with existing equity.
Press Release Issued by Fredun Pharmaceuticals Limited dated 08 October, 2026.
Press Release · 08 Oct 2026, 3:03 pm
Fredun Pharmaceuticals Accelerates Transformation into Branded Healthcare Platform Targeting Rapid Growth Fredun Pharmaceuticals is pivoting from OEM manufacturing to a 100% branded portfolio by 2029, targeting doubled revenue and profitability over the next 3–4 years. Key growth drivers include acquiring a 26% stake in Goodman Vetcare at a ₹300 crore valuation, buying pet-wellness brand Furlicks, and developing the WAGR platform. Manufacturing capacity is expanding with a ~40,000 sq. ft. utility block operational by Oct'26 plus 50,000 sq. ft. planned. Capital base increased following a 1.10 crore bonus share allotment on 17th Jul'26 and warrant conversions.
Revised Allotment of Rs. 182400 Equity Shares.
Others (Uncategorized) · 06 Oct 2026, 2:01 am
Fredun Pharmaceuticals Allots 1,82,400 Equity Shares on Warrant Conversion Fredun Pharmaceuticals' Board approved the allotment of 1,82,400 equity shares of face value Rs. 10 each on 3rd Oct'26, following the conversion of 60,800 preferential warrants by 10 non-promoter allottees. Originally allotted on 29th Dec'25 at an issue price of Rs. 1,250 per warrant, the entitlement was adjusted to three equity shares per warrant following a 1:2 bonus issue. The allotment occurred upon receipt of the remaining 75% balance consideration, ranking the new shares pari passu with existing equity.
Revised Outcome of Board Meeting Dated 03rd October, 2026.
Outcome · 06 Oct 2026, 1:50 am
Fredun Pharmaceuticals Allots 182,400 Equity Shares Post Warrant Conversion Fredun Pharmaceuticals approved the allotment of 1,82,400 fully paid-up equity shares (face value Rs. 10 each) on 3rd Oct'26, pursuant to the conversion of 60,800 preferential warrants across 10 non-promoter allottees following receipt of the balance consideration. Originally allotted on 29th Dec'25 at an issue price of Rs. 1,250 per warrant, the conversion ratio was adjusted to three equity shares per warrant following the company's 1:2 bonus issue. Post-allotment, 2,667 warrants remain outstanding for future conversion. The allotted shares rank pari passu with existing equity.
ALLOTMENT OF EQUITY SHARES PURSUANT TO CONVERSION OF WARRANTS.
Others (Uncategorized) · 03 Oct 2026, 11:13 pm
Fredun Pharmaceuticals Allots 1,82,400 Equity Shares on Warrant Conversion Fredun Pharmaceuticals' Board approved the allotment of 1,82,400 equity shares of face value Rs. 10 each on 3rd Oct'26 to 10 non-promoter allottees upon the conversion of 60,800 preferential warrants. Post the company's 1:2 bonus issue, each warrant issued at Rs. 1,250 entitled holders to three equity shares. Allottees paid the remaining 75% balance consideration to exercise conversion rights. Following this conversion, 2,667 warrants remain outstanding. The newly allotted shares will rank pari passu with existing equity shares.
Allotment of 1,82,400 Equity Shares to Non-Promoter Allottees pursuant to conversion of 60,800 Warrants into Equity Shares, consequent to the 1:2 Bonus Issue.
Others (Uncategorized) · 03 Oct 2026, 11:11 pm
Fredun Pharmaceuticals Allots 182,400 Equity Shares Following Warrant Conversion Fredun Pharmaceuticals approved the allotment of 1,82,400 fully paid equity shares of face value Rs. 10 each on 3rd Oct'26, following the conversion of 60,800 preferential warrants held by 10 non-promoter allottees. Originally issued on 29th Dec'25 at Rs. 1,250 per warrant (25% upfront), the warrant entitlement was adjusted to 3 equity shares per warrant following a 1:2 bonus issue. Full consideration has been received, with 2,667 warrants remaining outstanding for conversion. The newly allotted shares will rank pari passu with existing equity shares.
Revised Allotment of Equity Shares pursuant to conversion of warrants.
Others (Uncategorized) · 23 Sept 2026, 12:35 am
Fredun Pharmaceuticals Allots 3,61,599 Equity Shares on Warrant Conversion Fredun Pharmaceuticals Limited approved the allotment of 3,61,599 fully paid-up equity shares (face value Rs. 10 each) to 10 non-promoter allottees on 16th Sep'26 upon the conversion of 1,20,533 warrants originally issued on 29th Dec'25 at Rs. 1,250 per warrant. The allotment reflects warrant entitlement adjustments following the company's 1:2 bonus issue, converting each warrant into three equity shares upon receipt of the balance 75% consideration. Following this allotment, 7,467 warrants remain outstanding for conversion. The new shares rank pari passu with existing equity.
Revised Outcome of Board Meeting Dated 16th September, 2026
Outcome · 22 Sept 2026, 11:58 pm
Fredun Pharmaceuticals Allots Equity Shares Post Warrant Conversion Fredun Pharmaceuticals approved the allotment of 3,61,599 fully paid-up equity shares (face value Rs. 10 each) on 16th Sep'26 following the conversion of 1,20,533 warrants by 10 non-promoter allottees. Originally issued at Rs. 1,250 per warrant on 29th Dec'25, warrant entitlements were adjusted to 3 equity shares per warrant following a 1:2 bonus issue. The allotment follows receipt of the remaining 75% balance consideration, leaving 7,467 warrants outstanding for conversion. The newly allotted shares will rank pari passu with existing equity shares.
Press Release by FPL dated- 22-09-2026
Press Release · 22 Sept 2026, 2:50 pm
Fredun Pharmaceuticals Acquires 26% Stake in ₹300 Crore-Valued Goodman Vetcare Fredun Pharmaceuticals acquired a 26% stake in Goodman Vetcare, valued at ₹300 crore, strengthening its presence in animal health and veterinary retail. Goodman Vetcare's revenue grew at a 30% annual rate from ₹14.1 crore in FY24 to ₹23.6 crore in FY26. It targets revenues of ~₹40 crore in FY27, ~₹56 crore in FY28, and ~₹100 crore by FY31 via a PAN-India retail expansion of eight new stores across three cities. For FY26, Fredun reported revenue of ₹639.12 crore, EBITDA of ₹94.79 crore, and PAT of ₹33.21 crore.
Allotment of 271200 Equity Shares upon Conversion of Warrants.
Others (Uncategorized) · 17 Sept 2026, 2:28 am
Fredun Pharmaceuticals Allots 2,71,200 Equity Shares on Warrant Conversion Fredun Pharmaceuticals approved the allotment of 2,71,200 fully paid equity shares (face value Rs. 10 each) to 10 non-promoter investors on 16th Sep'26 following warrant conversions. Originally issued on 29th Dec'25 at Rs. 1,250 per warrant, the conversion ratio was adjusted to three equity shares per warrant following a 1:2 bonus issue. Conversion of 90,400 warrants was executed after receiving full balance consideration, with major allottees including Alchemy Long Term Ventures Fund, Alchemy Capital Management, and Ajay Kumar Aggarwal. Following this allotment, 37,600 warrants remain outstanding for conversion.
Allotment of 2,71,200 Equity Shares to Non-Promoter upon conversion of Warrants into Equity Shares.
Others (Uncategorized) · 17 Sept 2026, 2:22 am
Fredun Pharmaceuticals Allots 2.71 Lakh Shares Upon Warrant Conversion Fredun Pharmaceuticals approved the allotment of 2,71,200 equity shares (face value Rs. 10 each) to 10 non-promoter allottees on 16th Sep'26, following the conversion of 90,400 warrants allotted on 29th Dec'25. Adjusted for a 1:2 bonus issue, each warrant converted into three equity shares upon receipt of full consideration (original issue price: Rs. 1,250 per warrant). Key allottees include Alchemy Long Term Ventures Fund (72,000 shares) and Alchemy Capital Management (54,000 shares). Following this conversion, 37,600 warrants remain outstanding.
Press Release
Press Release · 15 Sept 2026, 3:57 pm
Fredun Pharmaceuticals Expands Pet-Wellness Brand Furlicks From 6 to 22 SKUs Fredun Pharmaceuticals Limited (FPL) announced a major phase-wise portfolio expansion for its acquired pet-wellness brand, Furlicks, expanding its lineup from 6 to 22 SKUs over the next 6–9 months. The rollout introduces 16 new products across diverse formats, moving beyond oral-dissolving strips into cold-extruded, air-dried, freeze-dried products, and functional biscuits. This expansion aims to build Furlicks into a differentiated, multi-format pet-wellness platform across India by leveraging FPL's internal manufacturing, R&D, and product development capabilities.
PRESS RELEASE
Press Release · 15 Sept 2026, 2:58 pm
Fredun Pharmaceuticals Expands Pet Wellness Brand Furlicks Portfolio from 6 to 22 SKUs Fredun Pharmaceuticals Ltd. announced the expansion of its pet wellness brand, Furlicks, scaling its product portfolio from 6 to 22 SKUs on 15th Sep'26. The move marks an accelerated push into the high-growth pet healthcare segment, aimed at strengthening its market presence and product offerings across diverse pet wellness categories.
Press Release issued by Fredun Pharmaceuticals Limited
Press Release · 08 Sept 2026, 5:28 pm
Fredun Pharmaceuticals Acquires Pet-Wellness Brand Furlicks From USV Fredun Pharmaceuticals Limited announced on 8th Sep'26 the acquisition of pet-wellness brand Furlicks from pharma major USV and its subsidiary Wellbeing Nutrition, marking its strategic entry into India’s pet-wellness market. Furlicks provides oral-strip pet supplement solutions spanning gut health, joint care, and multivitamins. FPL plans to leverage its manufacturing, R&D, and distribution infrastructure to scale the brand into a comprehensive pet-wellness platform, targeting an immediate expansion with 12 new SKUs in Phase 1 followed by 32 new SKUs in Phase 2.
Press Release issued by Fredun Pharmaceuticals Limited dated 04.09.2026
Press Release · 04 Sept 2026, 3:12 pm
Intimation regarding permission to trade and admission of Equity Shares to dealing on the National Stock Exchange of India
Others (Uncategorized) · 18 Aug 2026, 12:53 am
Fredun Pharmaceuticals to Commence Trading on the National Stock Exchange Fredun Pharmaceuticals Limited announced its equity shares have been permitted to trade on the National Stock Exchange (NSE) effective 17 Aug'26. The company, already listed on the BSE (Scrip Code: 539730), will trade under the NSE symbol FREDUN. This dual listing is expected to enhance liquidity and broaden the investor base for the stock. The equity shares have a face value of Rs. 10/- and the ISIN is INE194R01017. The move follows the approval granted by the NSE on 14 Aug'26.
Transcript of the Earnings Conference call held on 13th August, 2026 for Q1 FY27.
Transcript · 17 Aug 2026, 9:50 pm
Statement of Deviation or Variation For the Quarter Ended June 30, 2026.
Others (Uncategorized) · 15 Aug 2026, 4:06 am
Fredun Pharma: No Deviation in Fund Use, but Monitoring Agency Raises Flags For the quarter ended 30th Jun'26, Fredun Pharmaceuticals confirmed no deviation in utilizing the ₹111.53 crore raised via a preferential issue on 29th Dec'25. However, monitoring agency CARE Ratings raised observations regarding expenditure classification, fund routing, supporting documentation, and reconciliation of unutilized proceeds. Management maintains its classifications are appropriate within the disclosed objects and considers the matters non-deviations. The company is collating supporting records and undertaking a detailed reconciliation with its auditor and CARE Ratings to address the issues.
Monitoring Agency Report dated 14.08.2026
Others (Uncategorized) · 15 Aug 2026, 3:57 am
Fredun Pharma: Monitoring Agency Reports Deviation in Fund Use CareEdge Ratings' monitoring report for Q1'27 flags deviations in Fredun Pharma's use of preferential issue proceeds. A total of ₹13.21 crore was used for purposes not explicitly covered, including ₹1.91 crore on loan EMI/flat purchase under 'Capex' and ₹5.85 crore on statutory dues. Discrepancies were found in reported utilization figures: the company/CA reported utilization of ₹77.15 crore, while the monitoring agency calculated it at ₹79.80 crore. Consequently, unutilized proceeds are disputed—₹31.73 crore per agency vs. ₹21.47 crore reported by the company.
Audio Recording Q1 FY27 'Earnings Conference Call' of Fredun Pharmaceuticals Limited.
Audio / Video · 13 Aug 2026, 10:17 pm
Fredun Pharma Provides Audio Recording of Q1 FY27 Earnings Call Fredun Pharmaceuticals (BSE: 539730) has published the audio recording of its Q1 FY27 earnings conference call, held on 13th Aug'26. The call discussed the company's un-audited financial results for the quarter ended 30th Jun'26. As per SEBI regulations, the recording is now available on the company's investor relations website for shareholder access.
Intimation of Earnings Conference Call for the quarter Q1 of FY27.
Intimation · 13 Aug 2026, 11:30 am
Fredun Pharmaceuticals Schedules Q1 FY27 Earnings Conference Call Fredun Pharmaceuticals (BSE: 539730) has scheduled an earnings conference call to discuss its Q1 FY27 financial results. The call will be held on Thu, 13th Aug'26, at 11:30 AM IST. The company's management, including Managing Director Mr. Fredun Medhora, will be present. Interested parties can join via the provided registration link or dial-in numbers.
Newspaper Advertisement of the Un-Audited Financial Results for Quarter ended 30th June, 2026
Press Release · 06 Aug 2026, 8:37 pm
Fredun Pharma Reports Unaudited Financials for Q1 FY27 Fredun Pharmaceuticals announced its unaudited results for the quarter ended 30th Jun'26. Total income stood at ₹2,606.51 Lakh, while total expenses were ₹2,460.79 Lakh. Profit before tax was ₹145.72 Lakh, with a profit for the period of ₹104.90 Lakh. This translates to a Basic and Diluted EPS of ₹2.89. The company's total comprehensive income for the quarter was reported at ₹104.90 Lakh.
Press Release issued by Fredun Pharmaceuticals Limited
Press Release · 06 Aug 2026, 7:26 pm
Fredun Pharma Reports Stellar Q1 FY27 with 90% Revenue Growth Fredun Pharmaceuticals reported robust Q1 FY27 results with total income growing 90.4% YoY to ₹228.25 Cr. EBITDA surged 92.9% to ₹32.78 Cr, with the margin expanding by 18 bps to 14.36%. Net profit rose 94.6% YoY to ₹13.17 Cr, while basic EPS increased by 66.7% to ₹23.89. The company also allotted 1.10 crore bonus equity shares in a 2:1 ratio on 17th Jul'26, increasing paid-up capital from 55.13 lakh to 1.65 crore shares.